Posted by Michael Wonder on 08 Oct 2023
FDA approves Novartis Cosentyx as first intravenous formulation interleukin-17A antagonist for rheumatic diseases
6 October 2023 - First new intravenous treatment option in six years for adults with psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis.
Novartis announced today that the US FDA has approved an intravenous formulation of Cosentyx (secukinumab) for the treatment of adults with psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis.
